Niezen Sebastian, Diaz Del Castillo Humberto, Mendez Castaner Lumen A, Fornoni Alessia
School of Medicine Anahuac University Mexico City Mexico.
School of Medicine Universidad Autónoma de Guadalajara Guadalajara Mexico.
Endocrinol Diabetes Metab. 2019 May 17;2(3):e00072. doi: 10.1002/edm2.72. eCollection 2019 Jul.
Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end-stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targets in DKD with agents blocking the renin-angiotensin system confer superior renoprotection when compared to other agents. However, the effects on renal outcomes of antihyperglycaemic agents in these patients have not been reported or studied broadly until recent years. The intent of this article is to review the available data on safety, efficacy, impact on renal outcomes and pathophysiology implications of the most utilized antihyperglycaemic agents in DKD/ESRD.
糖尿病肾病（DKD）是导致糖尿病患者死亡和经济负担的主要原因，在发达国家约占终末期肾病（ESRD）病例的50%。多项研究已表明，与其他药物相比，使用阻断肾素-血管紧张素系统的药物使DKD患者达到血压目标可提供更好的肾脏保护作用。然而，直到近年来，这些患者使用抗高血糖药物对肾脏结局的影响尚未得到广泛报道或研究。本文旨在综述DKD/ESRD中最常用的抗高血糖药物的安全性、有效性、对肾脏结局的影响以及病理生理学意义的现有数据。
